Combination of glycosphingosomes and liposomal doxorubicin shows increased activity against dimethyl-α-benzanthracene-induced fibrosarcoma in mice

References

• TianSHirshfieldKMJabbourSKSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsFront Oncol2014427725346912
   PubMedGoogle Scholar
• MackallCLT-cell immunodeficiency following cytotoxic antineoplastic therapy: a reviewStem Cells2000181101810661568
   PubMedGoogle Scholar
• MackallCLFleisherTABrownMRLymphocyte depletion during treatment with intensive chemotherapy for cancerBlood1994847222122287919339
   PubMed Web of Science ®Google Scholar
• KimJJTannockIFRepopulation of cancer cells during therapy: an important cause of treatment failureNat Rev Cancer20055751652515965493
   PubMed Web of Science ®Google Scholar
• RamosPBentires-AljMMechanism-based cancer therapy: resistance to therapy, therapy to resistanceOncogene Epub2014929
   Google Scholar
• EllisLMHicklinDJResistance to targeted therapies: refining anticancer therapy in the era of molecular oncologyClin Cancer Res200915247471747820008847
   PubMed Web of Science ®Google Scholar
• SwannJBSmythMJImmune surveillance of tumorsJ Clin Invest200711751137114617476343
   PubMed Web of Science ®Google Scholar
• SmythMJThiaKYStreetSEDifferential tumor surveillance by natural killer (NK) and NKT cellsJ Exp Med2000191466166810684858
   PubMedGoogle Scholar
• BrutkiewiczRRSriramVNatural killer T (NKT) cells and their role in antitumor immunityCrit Rev Oncol Hematol200241328729811880205
   PubMedGoogle Scholar
• RenukaradhyaGJKhanMAVieiraMDuWGervay-HagueJBrutkiewiczRRType I NKT cells protect (and type II NKT cells suppress) the host’s innate antitumor immune response to a B-cell lymphomaBlood2008111125637564518417738
   PubMedGoogle Scholar
• CroweNYSmythMJGodfreyDIA critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomasJ Exp Med200296111912712093876
   PubMedGoogle Scholar
• SmythMJNK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcomaInt Immunol200820463118334503
   PubMedGoogle Scholar
• JamesEEAndrewJKWebbTJRaising the roof: the preferential pharmacological stimulation of Th1 and Th2 responses mediated by NKT cellsMed Res Rev2014341457623239102
   PubMedGoogle Scholar
• BrutkiewiczRRCD1d ligands: the good, the bad, and the uglyJ Immunol2006177276977516818729
   PubMed Web of Science ®Google Scholar
• MoritaMMotokiKAkimotoKStructure-activity relationship of α-galactosylceramides against B16-bearing miceJ Med Chem19953812217621877783149
   PubMedGoogle Scholar
• SriramVDuWGervay-HagueJBrutkiewiczRRCell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cellsEur J Immunol20053561692170115915536
   PubMedGoogle Scholar
• CarvalhoCSantosRXCardosoSDoxorubicin: the good, the bad and the ugly effectCurr Med Chem200916253267328519548866
   PubMed Web of Science ®Google Scholar
• RivankarSAn overview of doxorubicin formulations in cancer therapyJ Cancer Res Ther201410485385825579518
   PubMed Web of Science ®Google Scholar
• SingalPKIliskovicNDoxorubicin-induced cardiomyopathyN Engl J Med1998339139009059744975
   PubMed Web of Science ®Google Scholar
• TahoverEPatilYPGabizonAAEmerging delivery systems to reduce doxorubicin cardiotoxicity and improve the therapeutic index: focus on liposomesAnticancer Drugs201526324125825415656
   PubMed Web of Science ®Google Scholar
• KhanAKhanAADwivediVAhmadMGHakeemSOwaisMTuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino miceMol Med2007135–626627617622310
   PubMed Web of Science ®Google Scholar
• MarkanJLRekechenetskiyAHollerELjubimovaJYNanomedicine therapeutic approaches to overcome cancer drug resistanceAdv Drug Deliv Rev20136513–141866187924120656
   PubMedGoogle Scholar
• CandoniAMicheluttiASimeoneEDamianiDBaccaraniMFaninREfficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukemia despite expression of multidrug resistance-related proteinsEur J Haematol200677429329916856922
   PubMedGoogle Scholar
• BrutkiewiczRRLinYChoSHwangYKSriramVRobertsTJCD1d-mediated antigen presentation to natural killer T (NKT) cellsCrit Rev Immunol2003235–640341915030309
   PubMed Web of Science ®Google Scholar
• RobertsonFCBerzofskyJATerabeMNKT cell networks in the regulation of tumor immunityFront Immunol2014554325389427
   PubMed Web of Science ®Google Scholar
• NowakMSchmidt-WolfIGNatural killer T cell subsets in cancer, functional defects in prostate cancer and implications for immunotherapyCancers (Basel)2011333661367524212972
   PubMedGoogle Scholar
• InoueJIdeueRTakahashiDKubotaMKumazawaYLiposomal glycosphingolipids activate natural killer T cell-mediated immune responses through the endosomal pathwayJ Control Release20091331182318930085
   PubMedGoogle Scholar
• RichardsonDSJohnsonSAAnthracyclines in haematology: preclinical studies, toxicity and delivery systemsBlood Rev19971142012239481450
   PubMedGoogle Scholar
• AllenTMMartinFJAdvantages of liposomal delivery systems for anthracyclinesSemin Oncol200431651515717735
   PubMedGoogle Scholar
• LorussoVManzioneLSilvestrisNRole of liposomal anthracyclines in breast cancerAnn Oncol200718Suppl 6vi70vi7317591837
   PubMedGoogle Scholar
• FuXKongLTangMProtective effect of ocotillol against doxorubicin-induced acute and chronic cardiac injuryMol Med Rep20149136036424220651
   PubMedGoogle Scholar
• DattaSParajuliNTymoszukPReplenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1J Leukoc Biol201495685386624295829
   PubMedGoogle Scholar
• KhanMAOwaisMToxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine modelJ Antimicrob Chemother200658112513216709592
   PubMed Web of Science ®Google Scholar
• PereiraRLReisVOSemedoPInvariant natural killer T cell agonist modulates experimental focal and segmental glomerulosclerosisPLoS One201273e3245422427838
   PubMed Web of Science ®Google Scholar
• VivierEUgoliniSBlaiseDChabannonCBrossayLTargeting natural killer cells and natural killer T cells in cancerNat Rev Immunol201212423925222437937
   PubMed Web of Science ®Google Scholar
• SwannJBCoquetJMSmythMJGodfreyDICD1-restricted T cells and tumor immunityCurr Top Microbiol Immunol200731429332317593666
   PubMedGoogle Scholar
• HayakawaYTakedaKYagitaHIFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramideBlood200210051728173312176894
   PubMed Web of Science ®Google Scholar
• FallariniSPaolettiTOrsi BattagliniNLombardiGInvariant NKT cells increase drug-induced osteosarcoma cell deathBr J Pharmacol201216771533154922817659
   PubMedGoogle Scholar
• RichterJNeparidzeNZhangLClinical regressions and broad immune activation following combination therapy targeting human NKT cells in myelomaBlood2013121342343023100308
   PubMedGoogle Scholar
• LaCasseCJJanikashviliNLarmonierCBTh-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanismJ Immunol2011187126310631722075702
   PubMedGoogle Scholar
• ParekhVVWilsonMTOlivares-VillagómezDGycolipid antigen induces long term natural killer T cell anergy in miceJ Clin Invest200511592572258316138194
   PubMed Web of Science ®Google Scholar
• SriramVChoSLiPInhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cellsProc Natl Acad Sci U S A200299128197820212060764
   PubMedGoogle Scholar
• ThapaPZhangGXiaCNanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergyVaccine20092725–263484348819200815
   PubMed Web of Science ®Google Scholar